Mary Hobart

This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text Link to original article here Thank you to the participants who took part in these 2 Phase 3 clinical trials. CL Ward, M Hobart, N Jin, and T Skubiak are all full-time employees of Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Plain Language Summary What is this summary about? This is a summary of an article about centanafadine, a medication for Attention-Deficit/Hyperactivity Disorder (ADHD): 2 large-scale research studies with hundreds of participants were carried out in adults with ADHD to find out whether centanafadine was effective and whether most people were able to take it without serious or unexpected side effects for the treatment of ADHD over 6 weeks.

Significant outcomes The primary endpoint of the randomised study was not met. Numerical efficacy advantages were observed at other time points, and further research is needed to determine the specific value of brexpiprazole in the difficult-to-treat population of patients with borderline personality disorder. Brexpiprazole had a similar safety profile in borderline personality disorder to that established in schizophrenia and major depressive disorder.